Cumberland Pharmaceuticals Stock Alpha and Beta Analysis
| CPIX Stock | USD 2.26 0.01 0.44% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Cumberland Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Cumberland Pharmaceuticals over a specified time horizon. Remember, high Cumberland Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Cumberland Pharmaceuticals' market risk premium analysis include:
Beta (0.65) | Alpha 1.54 | Risk 13.65 | Sharpe Ratio 0.13 | Expected Return 1.76 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Cumberland |
Cumberland Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Cumberland Pharmaceuticals market risk premium is the additional return an investor will receive from holding Cumberland Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Cumberland Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Cumberland Pharmaceuticals' performance over market.| α | 1.54 | β | -0.65 |
Cumberland Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Cumberland Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Cumberland Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Cumberland Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Cumberland Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Cumberland Pharmaceuticals shares will generate the highest return on investment. By understating and applying Cumberland Pharmaceuticals stock market price indicators, traders can identify Cumberland Pharmaceuticals position entry and exit signals to maximize returns.
Cumberland Pharmaceuticals Return and Market Media
The median price of Cumberland Pharmaceuticals for the period between Sun, Nov 3, 2024 and Sat, Feb 1, 2025 is 2.12 with a coefficient of variation of 34.08. The daily time series for the period is distributed with a sample standard deviation of 0.61, arithmetic mean of 1.8, and mean deviation of 0.6. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Cumberland Pharmaceuticals Inc. Q3 2024 Earnings Call Transcript | 11/11/2024 |
2 | Acquisition by Krogulski Kenneth of 380 shares of Cumberland Pharmaceuticals at 1.18 subject to Rule 16b-3 | 11/18/2024 |
3 | Acquisition by Krogulski Kenneth of 380 shares of Cumberland Pharmaceuticals at 1.15 subject to Rule 16b-3 | 11/19/2024 |
4 | Acquisition by Krogulski Kenneth of 427 shares of Cumberland Pharmaceuticals at 1.13 subject to Rule 16b-3 | 11/20/2024 |
5 | Acquisition by Krogulski Kenneth of 427 shares of Cumberland Pharmaceuticals at 1.09 subject to Rule 16b-3 | 11/21/2024 |
6 | Acquisition by Krogulski Kenneth of 474 shares of Cumberland Pharmaceuticals at 1.09 subject to Rule 16b-3 | 11/25/2024 |
7 | CPIX Stock Surges Amidst Volatility in Pharmaceutical Sector | 11/27/2024 |
8 | Acquisition by Krogulski Kenneth of 474 shares of Cumberland Pharmaceuticals at 1.32 subject to Rule 16b-3 | 11/29/2024 |
9 | Cumberland Pharmaceuticals director James Jones buys 1,754 in stock | 12/05/2024 |
10 | Why Is Cumberland Pharmaceuticals Stock Trading Over 100 percent on Tuesday | 12/10/2024 |
11 | Acquisition by Krogulski Kenneth of 197 shares of Cumberland Pharmaceuticals at 2.19 subject to Rule 16b-3 | 12/12/2024 |
12 | Acquisition by Krogulski Kenneth of 197 shares of Cumberland Pharmaceuticals at 2.33 subject to Rule 16b-3 | 12/13/2024 |
13 | Acquisition by Krogulski Kenneth of 312 shares of Cumberland Pharmaceuticals at 2.21 subject to Rule 16b-3 | 12/16/2024 |
14 | Acquisition by Krogulski Kenneth of 312 shares of Cumberland Pharmaceuticals at 2.12 subject to Rule 16b-3 | 12/17/2024 |
15 | Acquisition by Krogulski Kenneth of 312 shares of Cumberland Pharmaceuticals at 2.19 subject to Rule 16b-3 | 12/18/2024 |
16 | Acquisition by Krogulski Kenneth of 266 shares of Cumberland Pharmaceuticals at 2.33 subject to Rule 16b-3 | 12/19/2024 |
17 | Acquisition by Krogulski Kenneth of 301 shares of Cumberland Pharmaceuticals at 2.35 subject to Rule 16b-3 | 12/20/2024 |
18 | Cumberland Pharmaceuticals Earns Hold Rating from Analysts at StockNews.com | 01/08/2025 |
19 | 3 US Penny Stocks With Market Caps Over 30M | 01/16/2025 |
About Cumberland Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Cumberland or other stocks. Alpha measures the amount that position in Cumberland Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Days Sales Outstanding | 114.37 | 90.05 | 81.05 | 55.38 | PTB Ratio | 0.9 | 0.86 | 0.99 | 0.94 |
Cumberland Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Cumberland Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Cumberland Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Cumberland Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Cumberland Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Cumberland Pharmaceuticals' management manipulating its earnings.
| 5th of March 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Cumberland Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Cumberland Stock Analysis
When running Cumberland Pharmaceuticals' price analysis, check to measure Cumberland Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cumberland Pharmaceuticals is operating at the current time. Most of Cumberland Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cumberland Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cumberland Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cumberland Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.